Intravenous Infusions Limited (IIL.gh) HY2023 Interim Report

Intravenous Infusions Limited (IIL.gh) listed on the Ghana Stock Exchange under the Pharmaceuticals sector has released its 2023 interim results for the half year.

For more information about Intravenous Infusions Limited (IIL.gh) reports, abridged reports, interim earnings results and earnings presentations visit the Intravenous Infusions Limited (IIL.gh) company page on AfricanFinancials.

Indicative Share Trading Liquidity

The total indicative share trading liquidity for Intravenous Infusions Limited (IIL.gh) in the past 12 months, as of 1st June 2023, is US$597.3471 (GHS6.69K). An average of US$50 (GHS558) per month.

Intravenous Infusions Limited 2023 interim results for the half year

Company Profile

Intravenous Infusions Limited (IIL) was incorporated in 1969 and began operations in 1974 as the first pharmaceutical company producing intravenous fluids in Ghana. The main business activity of IIL is the production of intravenous infusions for therapeutic purposes. Intravenous infusion therapy, commonly called IV, refers to the administration of fluids, drugs, or blood directly into the circulatory system through a vein. Intravenous Infusions Limited is listed on the Ghana Stock Exchange